Core Insights - Koninklijke Philips (PHG) reported earnings of €0.19 per share, remaining flat year over year, with sales decreasing 1.7% to €4.3 billion, but comparable sales increased 3% driven by growth across all segments [1][8] - The company achieved an 8% increase in comparable order intake year over year in the reported quarter, indicating solid market demand [1][8] Sales Performance - Comparable sales in growth geographies increased by 3%, with Personal Health driving a 5% growth, while Mature geographies also saw a 3% increase, primarily from North America [2] - Diagnosis & Treatment revenues declined 3.3% to €2.08 billion, with comparable sales up 1%, while Connected Care revenues decreased 0.9% to €1.20 billion, but comparable sales increased 5% [3] - Personal Health revenues grew 5.7% to €883 million, with comparable sales up 11%, reflecting strong performance in both growth and mature geographies [4] Operating Performance - Gross margin contracted by 140 basis points to 44.4%, while general & administrative expenses increased slightly to 3.6% of sales [5] - Philips achieved €222 million in savings through cost management and productivity initiatives, with adjusted EBITA increasing 2.9% to €531 million and EBITA margin expanding 50 basis points to 12.3% [6][8] - Diagnosis & Treatment's adjusted EBITA margin contracted to 11.8%, while Connected Care's margin expanded to 11.4% [7] Financial Position - As of September 30, 2025, cash and cash equivalents were €1.91 billion, total debt was €8.385 billion, and operating cash flow was €327 million, significantly up from €192 million year over year [10] - Free cash flow improved to €172 million compared to €22 million in the previous year [10] Future Guidance - Philips expects 1-3% growth in comparable sales for 2025, with adjusted EBITA margin projected between 11.3% and 11.8% [11]

Core Insights - Koninklijke Philips N.V. reported earnings of €0.08 per share in Q1 2025, a significant improvement from a loss of €1.07 per share in the same quarter last year [1] - The company's sales decreased by 1% year-over-year to €4.1 billion [1] Sales Performance - Comparable sales declined by 2% year-over-year, with a notable double-digit decline in China [2] - Personal Health segment saw a 1% growth, while Diagnosis & Treatment experienced a 4% decline due to a high comparison base [2] - Sales in growth geographies fell by 4% year-over-year, primarily due to the decline in China [3] - Diagnosis & Treatment revenues decreased by 3% year-over-year to €1.96 billion, with a 4% decline in comparable sales [4] - Personal Health revenues grew by 3% year-over-year to €811 million, with a 1% increase in comparable sales [5] Operating Details - Gross margin expanded by 130 basis points to 45.1% [6] - General & administrative expenses increased to 3.9% of sales, while selling expenses remained flat at 26.5% [6] - Adjusted EBITA declined by 8.8% year-over-year to €354 million, with an EBITA margin contraction of 80 basis points to 8.6% [7] Segment Performance - Diagnosis & Treatment's adjusted EBITA margin increased by 30 basis points to 9.5% [8] - Connected Care's adjusted EBITA margin contracted by 290 basis points to 3.5% [8] - Personal Health's adjusted EBITA margin remained stable at 15.2% [9] Financial Position - As of March 31, 2025, cash and cash equivalents were €1.19 billion, down from €2.4 billion at the end of 2024 [10] - Total debt decreased slightly to €7.568 billion [10] - Operating cash outflow was €933 million, compared to €171 million in the same quarter last year [10] - Free cash outflow increased to €1,091 million from €336 million year-over-year [10] Guidance and Outlook - Philips expects 1-3% comparable sales growth for 2025, with adjusted EBITA margin projected between 10.8% and 11.3% [11] - Free cash flow is anticipated to be slightly positive in 2025, following significant payouts related to recalls [11] - Previous guidance for 2025 included a similar sales growth expectation but a higher EBITA margin range of 11.8%-12.3% [12]